Most of us carry a quiet worry about memory loss later in life. For anyone whose parent or grandparent had dementia, that worry can feel very specific. Until recently, there was not much a healthy person could actually do with it.
A new study suggests that is starting to change.
Researchers found that a protein called phosphorylated tau 217 can estimate a healthy adult's risk of memory trouble over the next five to ten years.
The estimate combines the protein level with a person's age, sex and a common gene variant.
Also read: Eating cabbage may be linked to a lower risk of certain cancers
The findings, published November 16, 2026 in JAMA Neurology, come from more than 2,100 cognitively healthy adults between the ages of 60 and 90.
How the Mayo Clinic test works
The marker sits at the heart of Alzheimer's biology. Phosphorylated tau 217, or p-tau217, is a form of a brain protein that rises in the blood years before memory symptoms appear.
It tracks closely with the amyloid plaques seen in Alzheimer's disease.
The team combined baseline p-tau217 levels with three things already known about each person.
Also read: Your gut bacteria know when you eat, and it could change how your body absorbs food
Those were age, sex, and whether they carried APOE ε4, the gene variant most strongly linked to Alzheimer's risk.
The result is not a simple yes or no. It is a personal number, the estimated odds that a cognitively healthy person will develop mild cognitive impairment or dementia within five or ten years.
What the risk numbers actually look like
For a healthy 75-year-old in the study, a low p-tau217 reading put the five-year risk of mild cognitive impairment at about 7 percent.
A high reading pushed the same five-year risk to roughly 17 percent.
Also read: Normal B12 blood levels by age: what your test result actually means
Stretched to ten years, the low reading climbed to around 15 percent. The high reading reached about 35 percent.
Age mattered more than many people may expect. At age 85, a high p-tau217 level carried a five-year risk of mild cognitive impairment near 37 percent, the study reported.
"Absolute risk gives the biomarker result clinical context," said senior author Clifford R. Jack Jr., a Mayo Clinic neuroradiologist, in a Mayo Clinic release on EurekAlert.
Why doctors are not rolling this out tomorrow
The test is not a crystal ball, and the authors are clear that routine screening in people without symptoms is not recommended today.
Also read: Vitamin C after processed meat may block a key cancer reaction
Risk estimates still need to be validated in more diverse populations and with other versions of the p-tau217 assay.
What the work may change is the conversation inside the doctor's office once preventive drugs are available.
Large trials such as AHEAD 3-45 and TRAILBLAZER-ALZ 3 are already testing whether treatments can delay Alzheimer's in people who feel fine but carry brain changes.
For families watching a loved one with dementia today, a personal five- or ten-year number from a blood draw is not here yet.
Also read: Pink noise during sleep may help your brain flush the waste linked to Alzheimer's
The next step, the Mayo team says, is pairing the risk estimate with a treatment that actually moves it.
This article is made and published by Ida-Marie Palm Varbæk, who may have used AI in the preparation.
